STAT+: When biotech acquisitions spike, early-stage startups are prime targets, analysis shows
Experts are predicting a coming surge of mergers and acquisitions in biotech. And if history…
Category: biotechnology
.jpg)
FDA approves Lilly diabetes drug that analysts expect to be a big seller
The Food and Drug Administration said Friday it had approved Mounjaro, a new injection for…
Listen: A CEO’s arrest, Pfizer’s big deal, & Covid on the rise
Is the next Covid surge upon us? How do you make $350,000 a day in…
STAT+: A Caribou CAR-T treatment, backed by Nobel-winning science, shows blood-cancer remissions in first data reveal
Caribou Biosciences said Thursday that its CRISPR-edited T-cell therapy induced complete remissions in four of…
.jpg)
STAT+: Police reports detailing Seagen CEO’s arrest raise questions about biotech’s response
Seagen CEO Clay Siegall was arrested and charged with domestic assault after a drunken night…
STAT+: Roche anti-TIGIT cancer immunotherapy fails second clinical trial
Roche said Wednesday that its experimental cancer immunotherapy directed against a target called TIGIT suffered…
STAT+: A new biotech investment firm, headed by a pair of noteworthy VCs, seeks to ‘free the founders’
The way biotech veteran Alexis Borisy and entrepreneur Zach Weinberg see it, the venture capital…
STAT+: It took years, but the failure of Northwest Bio’s brain cancer vaccine is now in the open
After years of delays and excuses, Northwest Biotherapeutics finally disclosed on Tuesday the final results…
STAT+: Pfizer to buy BioHaven for $11.6 billion, raising hopes for the broader biotech market
Pfizer said Tuesday that it will purchase BioHaven, a maker for migraine drugs, for $11.6…
STAT+: Flagship Pioneering hires lobbyists, a first among biotech venture firms
WASHINGTON — Flagship Pioneering, the venture capital firm behind Moderna, is getting into the Washington…
STAT+: From burst bubble to medical marvel: How lipid nanoparticles became the future of gene therapy
Paddy Doherty leaned back in the narrow hospital bed and watched a bag of clear…
Listen: Succession at Biogen, surprises at Vertex, & a potential superspreader dinner
Who’s going to run Biogen? Does Aduhelm have a future? And is it OK to…
STAT+: Illumina, maker of a key tool for drug discovery, to try making new drugs itself
DNA sequencing giant Illumina announced Thursday that it would enter the field of drug discovery,…
STAT+: Researchers describe the human element in the alchemy behind the Moderna vaccine and other new medicines
Veteran vaccine developer Jacqueline Miller joined Moderna in May 2020, at the height of the…
STAT+: Biogen, fresh off major decisions on CEO and Aduhelm, faces next hurdles
Biogen, a stalwart of the global drug industry for the past four decades, is perilously…
STAT+: Biogen to replace CEO as it ‘substantially’ curbs spending on its Alzheimer’s drug
Biogen is replacing CEO Michel Vounatsos, the company said Tuesday, ending a five-year tenure in…
STAT+: FDA suspends early study of Vertex stem-cell therapy for type 1 diabetes
Vertex Pharmaceuticals said Monday that the Food and Drug Administration had suspended an early-stage clinical…
STAT+: Despite biotech slump, veterans of SVB and KKR launch investment firm
Two of the top health care investors at the investment bank SVB Securities and the…
Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic
Pfizer released news late Friday that Paxlovid, the antiviral currently subject to a big push…
STAT+: Biogen board slashes CEO’s bonus as Aduhelm sales and overall business struggle
Biogen CEO Michel Vounatsos had his bonus cut in half to “hold him accountable for…
STAT+: Startups are turning to a century-old technology to fuel a resurgence in neuro drug development
Biotechs are used to turning to genetics as guideposts in developing new medications. Now, a…
Listen: How cancer-killing cell therapies work, biotech’s endless downturn, & an FDA conundrum
Can rewired cells cure some patients’ cancer? Do biotech stocks ever go up? And why’s…
How Paxlovid came to be: From the germ of an idea to a vital tool against Covid
Charlotte Allerton, Pfizer’s head of medicine design, was making dinner — omelets — with her…
STAT+: A company developing a human blood substitute attempts a comeback, but IPO plans look dicey
Biopure, the disgraced developer of a failed human blood substitute, is attempting a comeback. It’s…
STAT+: Nkarta studies of engineered natural killer cells show complete remissions in patients with blood cancers
Nkarta said Monday that two experimental, off-the-shelf treatments, both made from engineered natural killer cells,…
STAT+: There’s a new crop of treatments for ADHD in kids. Are they any better?
Parents and doctors now have more tools than ever before to help kids manage symptoms…
STAT+: With milestones on the horizon, Guardant Health CEOs lay out their vision for cancer detection
SAN DIEGO — Bay Area biotech Guardant Health is closer than ever to its ultimate…
STAT+: What Regeneron’s purchase of Checkmate Pharma says about the state of biotech
There are a few angles through which to view Tuesday’s acquisition of Checkmate Pharmaceuticals by…
STAT+: In nation’s biotech hub, layoffs, closures, and mergers expected as part of an industry ‘correction’
Based on the unrelenting demand for more lab space in the Boston area, a boom…
STAT+: Cel-Sci’s CEO used private call to tip off select investors about cancer drug update
Geert Kersten, the CEO of drugmaker Cel-Sci, stopped communicating publicly soon after the company’s cancer…
Listen: Leana Wen on the pandemic’s new normal and whether Twitter is real life
Are we supposed to just get used to superspreader events? What’s going with Editas Medicine?…
STAT+: Editas Medicine names new CEO — its fourth — as delays, poor data hamper its gene-editing treatments
Editas Medicine announced the hiring of a new CEO on Thursday — the fourth top…
STAT+: Halozyme to acquire Antares for nearly $1B in bid to dominate drug delivery market
San Diego biotech Halozyme announced Wednesday that it plans to buy drug development and delivery…
STAT+: A $2.1 million price tag for Bluebird Bio’s gene therapy is cost-effective, analysis finds
As the U.S. health care system braces for expensive gene therapies, a new analysis suggests…
STAT+: Good fortunes continue for Sierra Oncology with $1.9 billion acquisition by U.K. pharma giant Glaxo
Sierra Oncology is having a very good year. On Wednesday, the small U.S. drugmaker said…
STAT+: Giving immunotherapy before surgery prevents lung cancer from returning, study says
Giving the immunotherapy Opdivo, made by Bristol-Myers Squibb, to lung cancer patients before surgery can…
STAT+: Private equity giant Carlyle to acquire biotech venture capital firm Abingworth
The Carlyle Group will acquire Abingworth, one of biotech’s oldest venture capital groups, it announced…
STAT+: Natural killer cells, primed with an antibody, induce remissions in patients with advanced lymphoma
An experimental immunotherapy involving so-called natural killer cells elicited complete remissions in a majority of…
Listen: What’s next for Roche, a debate over second boosters, & Vertex’s recent success
What’s on tap for Roche and its closely followed cancer immunotherapy? Are we all headed…
STAT+: Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies
Cassava Sciences conceded Tuesday that only a relative handful of patients with Alzheimer’s have been…
STAT+: Bluebird, troubled gene therapy maker, to lay off employees and reduce costs
Bluebird Bio is reducing expenses and laying off nearly a third of its employees to…
STAT+: Douglas Melton, noted stem cell researcher, leaves Harvard for Vertex to create diabetes treatments
Douglas Melton, one of the leading stem cell researchers in the world, is leaving Harvard…
STAT+: When a dire text message interrupted his talk, this doctor’s cancer research became painfully real
SAN DIEGO — If you’d seen him, you wouldn’t have known Scott Lippman was living…
STAT+: The biotech scorecard for the second quarter: 21 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second…
In the wake of big patent decision, it’s business as usual for CRISPR therapy developers
Earlier this month, the U.S. Patent and Trademark Office ruled that CRISPR patents key to…
STAT+: Vertex’s non-opioid painkiller meets goals in mid-stage studies
A novel pain drug from Vertex Pharmaceuticals met its goals in two mid-stage trials, the…
STAT+: By narrow margin, FDA advisory panel concludes Amylyx ALS drug hasn’t proven effectiveness
For archived live coverage of the hearing of the FDA’s advisory panel, click here. By…
STAT+: Tracking the FDA advisory panel on Amylyx Pharma’s ALS treatment
The Food and Drug Administration is convening a meeting of outside experts today to review…
STAT+: FDA review is critical of data on Amylyx ALS drug, but cites ‘regulatory flexibility’
Results from a single clinical trial of an experimental drug for ALS developed by Amylyx…
Listen: Helen Branswell on the evolving pandemic, plus the next FDA debate and the perks of being a CEO
Are Covid-19 vaccines a sustainable business? Was Aduhelm an aberration? And what comes after Omicron?…